MDXG News & Events

MiMedx Group announced the commercial launch of AMNIOFIX Thyroid Shields, a product line extension of the Company's AMNIOFIX dehydrated human amnion/chorion membrane allografts. "Injuries to the recurrent laryngeal nerve are a great concern during thyroid and parathyroid operations, particularly as damage to the vocal cord nerve can result in severe impairment to voice production and increased risk of aspiration," stated John Harper, Ph.D., MIMEDX Chief Scientific Officer and SVP, R&D and Medical Affairs. "This product line extension offers our proven AMNIOFIX placental allograft, in a configuration designed to address this complication and supported by clinical data. We are excited for the full commercial release of this product line as we continue cultivate more surgical use cases for our portfolio."

The company said, "For 2026, MIMEDX currently estimates net sales to be in a range of $340 to $360 million and for adjusted EBITDA margin to be in the mid-to-high teens. Longer-term, the Company continues to expect to achieve annual net sales growth in the low double-digits as a percentage with an Adjusted EBITDA margin above 20%."

Reports Q4 revenue $118.1M, consensus $106.78M. Joseph Capper, MiMedx CEO, commented, "MIMEDX delivered a record year of revenue and profitability in 2025, with fourth quarter results that included net sales growth of 27% year-over-year, net income of $15 million, an Adjusted EBITDA margin of 25% of net sales, and robust free cash flow. These results were driven by strong double-digit contributions in both Wound and Surgical, which grew 28% and 25%, respectively, reflecting exceptional commercial execution across the markets we serve. We were particularly pleased with the durable double-digit growth seen in Surgical, and we are keenly focused on the untapped clinical opportunities for our current and future products."